Investors Opt for P...
Health Care: Drugs
Halozyme Therapeutics Inc. (HALO: NASDAQ)
$11.11 -0.17 | -1.51%
02/09/12 - 04:00 PM ET
399.78K / 630.70K
Vol / Avg. Vol:11.35 / 11.28
Open / Prev. Close:10.90 - 11.35
Today's Range:5.54 - 11.62
52 Wk Range:18.61%
Performance YTD:TheStreet Rating:
Portfolios with HALO
- Portfolio NameUser Type
- UserIncomeGrowth
- ContributorBreakout Stocks Of The Week...
- ContributorStocks At New 52-Week Highs...
- ContributorStocks With Big Insider Buy...
- ProTudor Investment
- Userbarry216 Portfolio 1
- ProQVT Financial
- ContributorPharmaceutical Stock Short ...
- UserPART 5 JPMorgan 28th Annual...
- ContributorBarron's Research Reports 7...
Latest HALO Headlines from TheStreet
- Cramer's 'Mad Money' Recap: In Praise of Superb Execution (Final) 01.18.12 | 07:01 pm
- 'Mad Money Lightning Round': Go With Halozyme Therapeutics 01.18.12 | 07:01 pm
- 5 Stocks With Big Insider Buying 11.23.11 | 12:11 pm
- Insiders Trading HALO, TGI, WPO, MELI 11.17.11 | 10:11 am
- 7 Stocks Rising on Unusual Volume 10.17.11 | 02:10 pm
- Halozyme Stock Hits New 52-Week Low (HALO) 08.04.11 | 03:08 pm
- Stocks Under $10: Biotech Bargain Play
06.22.11 | 09:06 am - Halozyme Stock Hits New 52-Week Low (HALO) 03.22.11 | 10:03 am
- Layoffs Mount in 2010: What Does It Mean for 2011? 01.06.11 | 05:01 pm
- Biotech Losers: Cubist Pharma, Lexicon 10.19.10 | 02:10 pm
Press Releases for HALO
- Halozyme Announces Proposed Public Offering Of Common Stock - PR Newswire 02.09.12 | 04:02 pm
- HTI-501 Data Support Commencement Of Phase 2 Portion Of Clinical Trial - PR Newswire 01.31.12 | 04:01 pm
- Halozyme Therapeutics To Present At The 30th Annual J.P. Morgan Healthcare Conference - PR Newswire 01.04.12 | 04:01 pm
- Halozyme Therapeutics To Present At The Oppenheimer Annual Healthcare Conference On December 13 - PR Newswire 12.07.11 | 08:12 am
- ViroPharma And Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment Of Subcutaneous Cinryze® (C1 Esterase Inhibitor [human]) With Hyaluronidase (rHuPH20) - PR Newswire 12.06.11 | 08:12 am
- Halozyme Therapeutics To Host Third Quarter 2011 Financial Results Conference Call On November 7 - PR Newswire 11.02.11 | 08:11 am
- Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial - PR Newswire 10.27.11 | 07:10 pm
- Halozyme Therapeutics Announces Data From Two Phase 1 Studies Of PEGPH20 Demonstrating Targeting Of Hyaluronan In Tumor Stroma - PR Newswire 10.27.11 | 09:10 am
- Halozyme Therapeutics To Present Data On PEGPH20 At The Upcoming 2011 EORTC-NCI-ASCO Annual Meeting - PR Newswire 10.24.11 | 08:10 am
- Halozyme Announces Positive Results From Phase 2 Ultrafast Insulin Trials In Patients With Type 1 And Type 2 Diabetes - PR Newswire 10.21.11 | 08:10 am
Partner Headlines for HALO
- Priority Review for VPHM's Drug - Analyst Blog - Zacks 01.16.12 | 10:01 am
- ViroPharma's Seizure Drug Reaches UK - Analyst Blog - Zacks 12.14.11 | 10:12 am
- ViroPharma-Halozyme Drug Advances - Analyst Blog - Zacks 12.07.11 | 10:12 am
- Noteworthy Insider Buys In The Healthcare Sector Last Week - Seeking Alpha 11.29.11 | 08:11 am
- 3 Golden Cross Stocks Deeply Undervalued From Target Price - Seeking Alpha 11.04.11 | 11:11 pm
- ViroPharma Going Strong - Analyst Blog - Zacks 10.31.11 | 10:10 am
- ViroPharma, Halozyme Initiate Trial - Analyst Blog - Zacks 09.15.11 | 10:09 am
- EU Clears ViroPharma's Drug - Analyst Blog - Zacks 09.07.11 | 10:09 am
- VPHM's Epilepsy Drug Recommended - Analyst Blog - Zacks 06.28.11 | 10:06 am
- ViroPharma's HAE Drug Gets EU Nod - Analyst Blog - Zacks 06.16.11 | 10:06 am
